New combo therapy aims to boost survival for early oral cancer
NCT ID NCT07267286
Summary
This study is testing if adding an immunotherapy drug (tirellizumab) to standard chemotherapy before surgery works better than surgery alone for early-stage oral cancer. It will involve 60 patients who are randomly assigned to receive either the new drug combination followed by surgery, or just surgery. The main goal is to see if the new approach helps more patients live longer without their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun yat-sen memorial hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.